Science Explorer Back to mapMap
Discussion
Topic · Rheumatology

Otitis Media and Relapsing Polychondritis

Otitis Media and Relapsing Polychondritis is a research topic within Rheumatology. Science Explorer counts 10k research works in it since 1950. 10.6% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the research related to Relapsing Polychondritis, a rare autoimmune disease characterized by recurrent inflammation of cartilage and other tissues. It also encompasses studies on VEXAS syndrome, a recently identified autoinflammatory condition associated with somatic mutations in UBA1. The papers cover various aspects including clinical features, disease activity, therapeutic options, and the role of somatic mutations in these conditions.

  • Relapsing Polychondritis
  • VEXAS Syndrome
  • Autoinflammatory Disease
  • UBA1 Mutations
  • Cartilage Autoimmunity
  • Clinical Features
  • Therapeutic Options
  • Somatic Mutations
  • Disease Activity
  • Biological Drug Use
Research works
10k
fractional, since 1950
In the world top 10%
1.1k
per year above
Top-10% rate
10.6%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+31%
the tick is no change
Largest producer
United States
26% of the 10 largest, 2022-now
Otitis Media and Relapsing Polychondritis

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Otitis Media and Relapsing Polychondritis research?

By volume, the United States and China publish the most (447 and 236 works in 2022-now).

By volume, 2022-now

  1. 1 United States 447 works
  2. 2 China 236 works
  3. 3 France 165 works
  4. 4 Japan 157 works
  5. 5 United Kingdom 151 works
  6. 6 India 129 works
  7. 7 Germany 123 works
  8. 8 Spain 112 works
  9. 9 Italy 108 works
  10. 10 Türkiye 99 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 25.9%China: 13.7%France: 9.6%Japan: 9.1%6 others listed: 41.8%26%largest
United States447 · 25.9%China236 · 13.7%France165 · 9.6%Japan157 · 9.1%6 others listed723 · 41.8%

Shares of the rows listed above, not of the whole node.

Which institutions lead Otitis Media and Relapsing Polychondritis research?

By volume in 2022-now, Mayo Clinic publishes the most Otitis Media and Relapsing Polychondritis research, followed by Harvard University and Université Paris Cité.

By volume, 2022-now

  1. 1 Mayo ClinicUnited States 28 works
  2. 2 Harvard UniversityUnited States 21 works
  3. 3 Université Paris CitéFrance 21 works
  4. 4 Sorbonne UniversitéFrance 19 works
  5. 5 National Institutes of HealthUnited States 17 works
  6. 6 InsermFrance 17 works
  7. 7 Istanbul University-CerrahpaşaTürkiye 13 works
  8. 8 Assistance Publique – Hôpitaux de ParisFrance 13 works
  9. 9 Johns Hopkins UniversityUnited States 12 works
  10. 10 Universitat de BarcelonaSpain 12 works

Who are the leading researchers in Otitis Media and Relapsing Polychondritis?

The most-cited researchers publishing on Otitis Media and Relapsing Polychondritis include Gordon Henry Guyatt, Didier Raoult and Peter Libby.

  1. 1 Gordon Henry Guyatt Canada 315k citations
  2. 2 Didier Raoult France 232k citations
  3. 3 Peter Libby United States 226k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Otitis Media and Relapsing Polychondritis?

The most cited paper in Otitis Media and Relapsing Polychondritis is "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" (J. Charles Jennette et al., 2012), with 6,681 citations. Next come "Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop" (4,424) and "Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis" (2,775).

Most cited papers
#PaperReleasedCitations
1 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides J. Charles Jennette et al. · Arthritis & Rheumatism Open access 8 Oct 2012 6,681
2 Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop Douglas A. Jabs, Robert Burton Nussenblatt, James Todd Rosenbaum · American Journal of Ophthalmology Open access 19 Jul 2005 4,424
3 Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis John H. Stone et al. · New England Journal of Medicine Open access 14 Jul 2010 2,775
4 The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis Gene G. Hunder, Daniel A. Bloch, Beat A. Michel et al. · Arthritis & Rheumatism Aug 1990 2,552
5 The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis) Alfonse T. Masi, Gene G. Hunder, J. T. Lie et al. · Arthritis & Rheumatism Aug 1990 2,223
All 99 most cited papers, with filters and sorting

Where is Otitis Media and Relapsing Polychondritis research done?

The largest centres of Otitis Media and Relapsing Polychondritis research in 2022-now are Paris (France), Beijing (China), Istanbul (Türkiye) and Tokyo (Japan).

Largest cities, 2022-now

  1. 1 ParisFrance 74 works
  2. 2 BeijingChina 49 works
  3. 3 IstanbulTürkiye 38 works
  4. 4 TokyoJapan 35 works
  5. 5 LondonUnited Kingdom 31 works
  6. 6 MadridSpain 31 works
  7. 7 AnkaraTürkiye 24 works
  8. 8 BarcelonaSpain 24 works
  9. 9 ShanghaiChina 21 works
  10. 10 RomeItaly 20 works
See Otitis Media and Relapsing Polychondritis on the map

Where is the best place to study Otitis Media and Relapsing Polychondritis?

Among universities, judged by research, University of Groningen, Sorbonne Université and Université Paris Cité score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 20.38%fractional works in this field (log) →share of work in the world top 10% →University of Gronin…Harvard UniversitySorbonne UniversitéUniversité Paris Cité
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1University of GroningenNetherlands 74.938.2%7.8×12 +2.4%
2Sorbonne UniversitéFrance 74.818.2%12.9×19 +94.8%
3Université Paris CitéFrance 71.515.6%12.8×21 +21.1%
4Harvard UniversityUnited States 70.218.3%3.1×21 +6.5%
5Universitat de BarcelonaSpain 59.420.7%7.0×12 +72.8%
6Istanbul University-CerrahpaşaTürkiye 57.115.2%25.7×13 +45.4%
7Johns Hopkins UniversityUnited States 54.514.7%3.6×12 +73.2%
8University of CambridgeUnited Kingdom 47.035.3%3.1×8 -42.8%
9University College LondonUnited Kingdom 35.717.7%2.4×8 -7.1%
10Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 35.39.9%4.6×10 +53.3%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Otitis Media and Relapsing Polychondritis, country by country

Is Otitis Media and Relapsing Polychondritis research growing?

Output in 2022-2025 was 31% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Otitis Media and Relapsing Polychondritis.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Otitis Media and Relapsing Polychondritis as a percentage of every work published that year, 0.0096% in 2024.

still counting0.0050%0.010%0.015%Otitis Media and Relapsing Polychondritis0.012% in 202519801990200020102020

Fractional works of Otitis Media and Relapsing Polychondritis over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Otitis Media and Relapsing Polychondritis10.7% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Otitis Media and Relapsing Polychondritis. Posts are plain text and can be reported.